BNF July 2022 Update

This update contains 3 significant changes, 5 new monographs, and 2 new preparations.

Significant Changes:

• Anagrelide: risk of thrombosis, including cerebral infarction, if treatment discontinued abruptly [MHRA/CHM advice].
• Denosumab (Prolia®): should not be used in patients under 18 years due to the risk of serious hypercalcaemia [MHRA/CHM advice].
• Tacrolimus: updated pregnancy, breast-feeding and monitoring advice.

New Monographs:

• Exkivity® [mobocertinib].
• Kerendia® [finerenone].
• Netildex® [dexamethasone with netilmicin].
• Nettacin® [netilmicin].
• Tenkasi® [oritavancin].

New Preparations:

• Dailiport® [tacrolimus]
• Ogluo® [glucagon].